Acerta Pharma v. MSN Pharmaceuticals: Acalabrutinib ANDA Consent Judgment
Acerta Pharma B.V. filed a Hatch-Waxman infringement action in Delaware against MSN Pharmaceuticals over five patents protecting acalabrutinib maleate 100 mg tablets — the active ingredient in Calquence. The case resolved in 346 days via a consent judgment that enjoins MSN from commercialising its generic product outside the terms of a confidential settlement agreement.
Hatch-Waxman ANDA battle over Calquence resolves by consent
On 10 January 2025, Acerta Pharma B.V. — the AstraZeneca subsidiary that holds the acalabrutinib patent estate — filed suit in the District of Delaware against MSN Pharmaceuticals, Inc., asserting infringement of five U.S. patents: US9,290,504; US9,758,524; US10,239,883; US10,272,083; and US11,059,829. The triggering event was MSN’s ANDA No. 220055, a regulatory application seeking FDA approval to market generic acalabrutinib maleate 100 mg base equivalent oral tablets ahead of patent expiry.
The case closed on 22 December 2025 via a consent judgment entered by Judge Gregory B. Williams. The judgment formally enjoins MSN — including its affiliates, successors, and assigns — from making, using, selling, offering for sale, importing, or distributing its generic acalabrutinib product except as specifically authorised under a separate, confidential settlement agreement. The 30-month Hatch-Waxman regulatory stay tied to the ANDA was simultaneously terminated by the court order, suggesting the parties agreed on a future entry date negotiated privately.
Resolving in under twelve months is consistent with a negotiated commercial settlement rather than a litigated outcome: both parties avoided the cost and uncertainty of a full bench trial. The specific authorised launch date for MSN’s generic — a critical commercial variable — remains confidential within the settlement agreement and is not disclosed in the public record. The court retained jurisdiction to enforce both the consent judgment and the underlying settlement, meaning compliance obligations persist beyond the case closure date.
Filing to Consent Judgment in 346 days
346 days — resolved within a single calendar year, faster than the typical ANDA trial track
Consent judgment entered: what the agreed order means for both parties
Consent judgment differs from a litigated verdict
A consent judgment is a court order entered with the agreement of all parties — it carries the same enforcement weight as a contested judgment but reflects negotiated terms rather than a judicial finding on the merits. Here, the Delaware District Court retains jurisdiction to enforce compliance, meaning Acerta/AstraZeneca can return to court if MSN breaches the injunction or the underlying settlement agreement without needing to file a new action.
Negotiated injunctionAcerta secures an injunction without a trial risk
Acerta Pharma (AstraZeneca) obtains a court-enforceable injunction across all five asserted patents, blocking MSN’s generic acalabrutinib from market except on terms Acerta agreed to privately. The patents are not adjudicated valid or invalid — they are simply not tested — which preserves their enforceability against future ANDA filers. A negotiated entry date, if agreed, allows Acerta to control genericisation timing for Calquence.
Injunction securedMSN accepts injunction; launch terms governed by settlement
MSN Pharmaceuticals is enjoined from commercialising its ANDA No. 220055 product outside the settlement agreement’s authorised terms. The Hatch-Waxman 30-month stay is terminated, which is a standard feature of settled ANDA cases — it does not accelerate FDA approval. MSN likely negotiated a defined future launch window in return for dropping any patent validity challenge, avoiding the cost and downside risk of a full bench trial on five patents.
Agreed entry date likelyCalquence generic entry timeline remains confidential but controlled
For payers, oncology pharmacies, and competing generic filers, the settlement leaves market entry timing opaque. Acerta’s ability to negotiate settlement across five patents — including composition and method claims — suggests a strong patent position that discouraged MSN from pursuing an IPR or full validity challenge. Other ANDA applicants for acalabrutinib generics will face the same patent wall and may reach similar negotiated outcomes.
Patent wall intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Acerta Pharma B.V. | Individual | AstraZeneca subsidiary — holder of the acalabrutinib (Calquence) patent estateSearch in Eureka ↗ |
| Defendant | Msn Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for acalabrutinib tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Acerta Pharma B.V.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Acerta Pharma B.V.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Acerta Pharma B.V.Search in Eureka ↗ |
| Defendant counsel | Bradford C. Frese | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Green , Jr. | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Janine A. Carlan | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Megan C. Haney | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Richard J. Berman | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert Karl Hill | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Saukshmya Trichi | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Cole Schotz, PC | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Seitz, Van Ogtrop & Green PA | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is a fully negotiated court order rather than a merits ruling — the court made no findings on patent validity, claim construction, or infringement. The injunction’s scope tracks the five asserted patents and covers all commercialisation acts by MSN and its affiliates. The carve-out ‘except as specifically authorised pursuant to the Settlement Agreement’ is the operative commercial term: it embeds a private licence or entry-date authorisation that governs MSN’s future market access. The stay termination clause is procedurally significant, clearing the regulatory pathway without requiring further court action.
US10272083B2 & US11059829B2 — acalabrutinib BTK inhibitor formulations
US10272083B2 and US11059829B2 are two of five patents asserted in this action, all directed to acalabrutinib — a second-generation, covalent Bruton’s tyrosine kinase (BTK) inhibitor marketed as Calquence for B-cell malignancies including CLL and MCL. The patents in the estate span composition of matter, salt forms, and pharmaceutical formulations, with application dates reflecting AstraZeneca/Acerta’s layered patent filing strategy to extend protection across multiple dimensions of the product.
Acalabrutinib represents a significant commercial asset for AstraZeneca, with Calquence generating multi-billion-dollar annual revenues in the haematologic oncology market. The breadth of the five-patent assertion — encompassing US9,290,504; US9,758,524; US10,239,883; US10,272,083; and US11,059,829 — reflects a deliberate strategy to create overlapping IP barriers against generic entry. For competing BTK inhibitor developers and generic pharmaceutical companies, these patents represent a substantial freedom-to-operate hurdle that is unlikely to be resolved without either litigation or a negotiated licence.
Should you run an FTO against the acalabrutinib patent estate?
Any pharmaceutical company developing a generic, biosimilar-adjacent, or next-generation BTK inhibitor in the acalabrutinib chemical space should treat these five patents as a live FTO concern. The consent judgment leaves all five unadjudicated and fully enforceable. Generic filers beyond MSN — whether pursuing ANDA, 505(b)(2), or international regulatory pathways — should map their formulation, salt form, and synthesis route against each asserted patent before committing to development spend.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to run structured freedom-to-operate analyses across the acalabrutinib patent family, identify claim-level overlap with candidate formulations, and surface prior art relevant to each patent’s validity. With five patents and a confidential settlement providing no claim construction guidance, a systematic Eureka FTO review is the fastest way to identify design-around opportunities or IPR candidates before filing an ANDA.
Run a freedom-to-operate analysis on US10272083B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving oncology small-molecule patents
Cases filed in Delaware District Court asserting BTK inhibitor or oncology small-molecule patents under the Hatch-Waxman framework, resolved by consent judgment or settlement.
What this case signals for the BTK inhibitor generic IP landscape
A fast, confidential consent judgment over five acalabrutinib patents sends a clear signal to the broader oncology generics market.
Five-patent assertion strategy deters validity challenges in ANDA cases
Acerta asserted five patents spanning composition, formulation, and method claims. Challenging all five via IPR or at trial represents a substantial cost and risk for a generic filer. MSN’s decision to settle rather than litigate suggests the breadth of the patent estate materially influenced the calculus — a pattern other branded oncology companies are likely to replicate.
Consent judgments preserve enforceability against future ANDA filers
Because no court ruled on validity or infringement, all five patents emerge from this case with their enforceability intact. Any subsequent generic applicant for acalabrutinib maleate 100 mg tablets faces the same unadjudicated patent wall, with no prior art findings or claim constructions from this litigation to leverage.
B.V. v Msn — key questions answered
Acerta Pharma asserted five U.S. patents: US9,290,504; US9,758,524; US10,239,883; US10,272,083; and US11,059,829. All relate to acalabrutinib — the active ingredient in AstraZeneca’s Calquence — and were triggered by MSN’s ANDA No. 220055 seeking FDA approval for generic acalabrutinib maleate 100 mg tablets.
The consent judgment enjoins MSN and its affiliates from making, selling, offering for sale, importing, or distributing its generic acalabrutinib product except as authorised under a confidential settlement agreement. MSN likely negotiated a defined future launch date in exchange for dropping any patent validity challenge. The court retained jurisdiction to enforce compliance.
The 30-month regulatory stay under 21 U.S.C. § 355(j)(5)(B)(iii) is automatically triggered when a branded company sues an ANDA filer within 45 days of a Paragraph IV certification. When the parties settled, the stay became moot and was formally terminated by the court order. This is standard in settled ANDA cases and does not in itself accelerate FDA approval of MSN’s generic product.
No. A consent judgment reflects a negotiated agreement — the court made no findings on patent validity, enforceability, or infringement. All five asserted patents emerge from this case with their legal status unchanged and fully enforceable against future generic applicants, who cannot rely on any prior art findings or claim constructions from this litigation.
The settlement controls the timing of MSN’s generic acalabrutinib entry through a confidential authorised launch date. For the broader market, the five-patent assertion strategy — spanning composition, salt, and formulation claims — signals that other ANDA filers will face the same unadjudicated patent wall. Payers and competitors should monitor AstraZeneca’s public disclosures on Calquence exclusivity for signals on expected generic entry timing.
PatSnap Eureka searches patents and litigation data to answer instantly.